174 related articles for article (PubMed ID: 38315147)
1. Antibody-Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling.
Sankar AP; Cho HM; Shin SU; Sneh T; Ramakrishnan S; Elledge C; Zhang Y; Das R; Gil-Henn H; Rosenblatt JD
Cancer Res Commun; 2024 Mar; 4(3):738-756. PubMed ID: 38315147
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases.
Shin SU; Cho HM; Das R; Gil-Henn H; Ramakrishnan S; Al Bayati A; Carroll SF; Zhang Y; Sankar AP; Elledge C; Pimentel A; Blonska M; Rosenblatt JD
Cells; 2021 Oct; 10(11):. PubMed ID: 34831127
[TBL] [Abstract][Full Text] [Related]
3. Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling.
Shen M; Jiang YZ; Wei Y; Ell B; Sheng X; Esposito M; Kang J; Hang X; Zheng H; Rowicki M; Zhang L; Shih WJ; Celià-Terrassa T; Liu Y; Cristea I; Shao ZM; Kang Y
Cancer Cell; 2019 Jan; 35(1):64-80.e7. PubMed ID: 30612941
[TBL] [Abstract][Full Text] [Related]
4. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
5. Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers.
Camorani S; Crescenzi E; Gramanzini M; Fedele M; Zannetti A; Cerchia L
Sci Rep; 2017 Apr; 7():46659. PubMed ID: 28425453
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
[TBL] [Abstract][Full Text] [Related]
7. Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth.
Yokoyama Y; Ramakrishnan S
Int J Cancer; 2004 Oct; 111(6):839-48. PubMed ID: 15300795
[TBL] [Abstract][Full Text] [Related]
8. Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.
Maiti A; Qi Q; Peng X; Yan L; Takabe K; Hait NC
Int J Oncol; 2019 Jul; 55(1):116-130. PubMed ID: 31059004
[TBL] [Abstract][Full Text] [Related]
9. Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer.
Zhang D; Sun B; Zhao X; Ma Y; Ji R; Gu Q; Dong X; Li J; Liu F; Jia X; Leng X; Zhang C; Sun R; Chi J
Mol Cancer; 2014 Sep; 13():207. PubMed ID: 25200065
[TBL] [Abstract][Full Text] [Related]
10. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
[TBL] [Abstract][Full Text] [Related]
11. Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway.
Peng B; He R; Xu Q; Yang Y; Hu Q; Hou H; Liu X; Li J
Pharmacol Res; 2019 Apr; 142():1-13. PubMed ID: 30735802
[TBL] [Abstract][Full Text] [Related]
12. Endothelium-Dependent Induction of Vasculogenic Mimicry in Human Triple-Negative Breast Cancer Cells Is Inhibited by Calcitriol and Curcumin.
Morales-Guadarrama G; Méndez-Pérez EA; García-Quiroz J; Avila E; García-Becerra R; Zentella-Dehesa A; Larrea F; Díaz L
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887002
[TBL] [Abstract][Full Text] [Related]
13. EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells.
Möller Y; Siegemund M; Beyes S; Herr R; Lecis D; Delia D; Kontermann R; Brummer T; Pfizenmaier K; Olayioye MA
PLoS One; 2014; 9(9):e107165. PubMed ID: 25198428
[TBL] [Abstract][Full Text] [Related]
14. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
Rigiracciolo DC; Santolla MF; Lappano R; Vivacqua A; Cirillo F; Galli GR; Talia M; Muglia L; Pellegrino M; Nohata N; Di Martino MT; Maggiolini M
J Exp Clin Cancer Res; 2019 Feb; 38(1):58. PubMed ID: 30728047
[TBL] [Abstract][Full Text] [Related]
15. Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with α5β1 integrin in glioma.
Kesanakurti D; Chetty C; Dinh DH; Gujrati M; Rao JS
Oncogene; 2013 Jan; 32(3):327-40. PubMed ID: 22349830
[TBL] [Abstract][Full Text] [Related]
16. Role of EGFR expression levels in the regulation of integrin function by EGF.
Vial D; McKeown-Longo PJ
Mol Carcinog; 2016 Jun; 55(6):1118-23. PubMed ID: 26053065
[TBL] [Abstract][Full Text] [Related]
17. A chalcone-syringaldehyde hybrid inhibits triple-negative breast cancer cell proliferation and migration by inhibiting CKAP2-mediated FAK and STAT3 phosphorylation.
Jin XX; Mei YN; Shen Z; Zhu JF; Xing SH; Yang HM; Liang G; Zheng XH
Phytomedicine; 2022 Jul; 101():154087. PubMed ID: 35429924
[TBL] [Abstract][Full Text] [Related]
18. New Peptide-Drug Conjugates for Precise Targeting of SORT1-Mediated Vasculogenic Mimicry in the Tumor Microenvironment of TNBC-Derived MDA-MB-231 Breast and Ovarian ES-2 Clear Cell Carcinoma Cells.
Charfi C; Demeule M; Currie JC; Larocque A; Zgheib A; Danalache BA; Ouanouki A; Béliveau R; Marsolais C; Annabi B
Front Oncol; 2021; 11():760787. PubMed ID: 34751242
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced antitumor efficacy.
Shin SU; Cho HM; Merchan J; Zhang J; Kovacs K; Jing Y; Ramakrishnan S; Rosenblatt JD
Mol Cancer Ther; 2011 Apr; 10(4):603-14. PubMed ID: 21393427
[TBL] [Abstract][Full Text] [Related]
20. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]